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ABSTRACT 
Chronic cluster headache is a rare, highly disabling primary headache condition.  When 
medically intractable, occipital nerve stimulation can offer effective treatment.  Open-label 
series have provided data on small cohorts only.  We analyzed 51 subjects to evaluate the 
long-term outcomes of highly intractable chronic cluster headache with occipital nerve 
stimulation.  Patients with intractable chronic cluster headache were implanted with occipital 
nerve stimulators during the period 2007-2014.  Primary endpoint was improvement in daily 
attack frequency.  Secondary endpoints included attack severity, attack duration, quality of 
life measures, headache disability scores and adverse events.  We studied 51 patients (35 
male): mean age at implant 47.78 years (range 31-70) and mean follow-up 39.17 months 
(range 2-81 months).  Nineteen patients had other chronic headache types in addition in 
chronic cluster headache.  At final follow-up, there was a 46.1% improvement in attack 
frequency (p<0001) across all patients, 49.5% (p<0.001) in those with cluster headache alone 
and 40.3% (p=0.036) in those with multiple phenotypes.  There were no significant 
differences in response of those with or without multiple headache types.  The overall 
response rate (defined as at least a 50% improvement in attack frequency) was 52.9%.  
Significant reductions were also seen in attack duration and severity.  Improvements were 
noted in headache disability scores and quality of life measures.  Triptan use of responders 
dropped by 62.56% resulting in significant cost savings.  Adverse event rates were highly 
favorable.  Occipital nerve stimulation appears to be a safe and efficacious treatment for 
highly intractable chronic cluster headache even after a mean of over three-years follow-up.   
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INTRODUCTION 
Cluster headache is a primary headache disorder characterized by bouts during which patients 
experience multiple attacks of severe unilateral pain associated with cranial autonomic 
features [7].  When attacks occur for over one year with remissions lasting less than one 
month then the condition is said to be chronic.  Cluster headache has a prevalence of around 
0.1% [20] with 10-15% of this group suffering chronic cluster headaches (CCH) [8]. 
Cluster headache can be successfully treated with a range of oral and injectable medications. 
However, a proportion of CCH patients are intractable to all available medications.  Although 
a unifying definition of refractory CCH is still awaited, guidelines from Goadsby et al. 
suggest that patients meet diagnostic criteria for CCH and have failed at least four classes of 
drugs from verapamil, lithium, methysergide melatonin, topiramate or gabapentin, with at 
least two from the first three agents [6].  More recently, the European Headache Federation 
defined refractory CCH as patients meeting ICHD-3beta criteria who continue to suffer from 
at least three severe attacks a week despite adequate trials of at least three of the following: 
verapamil, lithium, oral or IV steroids, greater occipital nerve blockade, topiramate, 
methysergide, ergots, civamide or long-acting triptans [16].  Due to the highly disabling 
nature of intractable CCH, destructive surgical approaches to treatment have been 
investigated with disappointing results.  Neurostimulation techniques involving peripheral 
and central targets have now emerged as promising therapies.  Peripheral stimulation of the 
occipital nerve has been investigated as a potentially useful treatment for chronic migraine 
(CM) in a limited number of randomized control studies [11; 21; 24] and for CCH in a 
number of small open label series [1; 2; 4; 5; 12; 14; 19; 22]. 
We report the long-term follow-up of 51 intractable CCH patients treated with occipital nerve 
stimulation (ONS).   
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METHODS 
Patients 
Patients with intractable CCH seen in the headache clinic at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London, UK were offered ONS.  Patients were 
reviewed and operated on by a single multidisciplinary headache team, consisting of 
headache specialists, neurosurgeons and headache specialist nurses with access to psychology 
and psychiatry services.  Implants took place over a period from October 2007 to June 2014.  
Follow-up visits occurred every three months for the first year and then every six to twelve 
months thereafter.  All patients fulfilled the International Classification of Headache 
Disorders (ICHD) 2nd edition and revised ICHD-3beta diagnostic criteria for CCH as well as 
also the proposed criteria for intractable CCH [6; 8].  Under the supervision of our 
institution’s Clinical Effectiveness Supervisory Committee with arrangements for clinical 
governance, consent and audit, we offered ONS to patients with intractable CCH. The 
procedure was provided on the basis of a “humanitarian intervention”. In addition, ethics 
board approval for data collection and publication was granted by Northwick Park Hospital 
Research Ethics Committee, Hampstead, London, UK.  
 
Surgical Procedure 
ONS systems were implanted as described elsewhere [9].  Bilateral octad electrodes were 
placed in all patients (Table 1).   Medtronic systems were implanted in 48 (94.1%) and St 
Jude Medical systems in 3 (5.9%).  Patients did not undergo trial stimulation.  Implantable 
pulse generators (IPG) were placed in subclavicular or abdominal pockets dependent on 
patient preference. 
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At initial programming, frequency was set at 60Hz with a pulse width of 240µs.  Polarity of 
the electrodes was adjusted during follow up visits to ensure comfortable bilateral 
paranesthesia in the occipital region.  Patients used continuous stimulation but were able to 
adjust the amplitude.  Medications were changed at the discretion of the headache specialist.   
 
Data Collection 
Data were collected prospectively and entered onto a clinical database (Microsoft Excel, 
Microsoft Corporation, Redmond, WA, USA).  Data including demographics, diagnosis, 
attack frequency, previous and current treatments, and adverse events were recorded.  
Patients prospectively completed headache diaries recording the frequency, severity on a 
verbal rating scale (VRS; 0=no pain to 10=extreme pain) and duration of cluster headache 
attacks for one month prior to implant and two weeks prior to each follow-up visit.  Diaries 
were used to calculate mean daily attack frequency, severity and duration over these periods 
of time.  Where multiple headache types were present, patients completed separate diaries for 
each. 
Migraine Disability Assessment Scores (MIDAS) and Headache Impact Test 6 Scores (HIT-
6) were recorded pre- and post-ONS to monitor headache related disability.  Although 
MIDAS has not been validated for its use in CCH, it has been used extensively in the 
assessment of other primary headache disorders including cluster headache [22].  Euro-QoL, 
Short Form 36 Questionnaires (SF36), Beck Depression Inventory II (BDI-II), Hospital 
Anxiety (HAD-A) and Hospital Depression (HAD-D) Scores were used to monitor quality of 
life and mental state.  
Primary outcome measure was improvement in mean daily attack frequency at final follow-
up compared to baseline.  Response was defined as a 50% or more reduction in mean daily 
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attack frequency.  Secondary outcome measures included attack severity, attack duration, 
headache-related disability scores, affective measures and quality of life scores. 
 
Statistics 
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. 
Int.).  A last observation carried forward technique was used in the case of missing data.  
Descriptive statistics were summarized as appropriate.  Data is presented as mean ±SD, range 
and frequencies.  Paired and independent t-tests were used to compare treatment effect as 
appropriate.  All statistical tests were two-sided with a significance level of 95%.   
 
RESULTS 
Patient demographics 
Thirty-five men and 16 women with a mean age of 47.78 years (range 31-70 years) were 
implanted.  Mean duration of chronic cluster headache at implantation was 7.88 years (range 
2-43 years). The mean number of medications prior to implant was 12.57 ±2.91 (range 7-21).  
(Supplementary Table 1).  Nineteen patients (37.3%) had other chronic headaches in addition 
to CCH: 13 had CCH and CM, three had CCH and short-lasting unilateral neuralgiform 
headache attacks (SUNHA) and three CCH, CM and SUNHA.  All kept separate diaries for 
each phenotype throughout follow-up.  Table 2 provides demographic data for the cohort.     
Whole Cohort 
Mean follow-up time was 39.17 months (range 2-81).  At follow-up four patients had had 
their implants removed, 3 for lack of efficacy and one for intractable neck pain secondary to 
lead tethering.  Figure 1a shows the percentage improvement in daily attack frequency over 
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the follow-up period.  At final follow-up, 52.9% (n=27) of patients achieved at least a 50% 
reduction in daily attack frequency (i.e. were classed as responders).  Mean daily attack 
frequency fell by 46.1% (±43.7) (p<0.001).  Over the course of follow-up, 47.1 % (n=24) 
patients reported over six months of continuous pain-freedom.  The mean duration of pain 
freedom was 16.25 months (range 6-48).  Significant reductions were also seen in attack 
intensity (26.4%) and duration (43.3%) (Table 3).  Across the cohort, significant 
improvements were observed in MIDAS (-34.92), HIT-6 (-7.05), HAD-A (-2.04), HAD-D (-
2.82) and BDI-II (-4.77) scales.  Quality of life scores showed improvements but only that in 
SF-36 mental composite score was significant (Table 4).  Non-responders to ONS failed to 
show any improvement in any headache disability, affect or quality of life scores.  
Responders showed significant improvements in all headache disability scores and affective 
scores as well as SF-36 mental composite score (Supplementary Table 2).  Patient estimate of 
overall CCH improvement was 53.7% (±38.60).  Differences in outcomes of responders and 
non-responders are shown in Supplementary Table 3. 
Chronic cluster headache alone 
In the 32 patients with CCH alone, mean follow-up time was 42.59 months (range 2-81).  
Figure 1b shows the change in daily attack frequency over follow-up.  A 50% response was 
observed in 53.1% (n=17) patients.  Mean daily attack frequency reduced by 49.5% (±43.84) 
(p<0.001).  Significant improvements were also seen in daily attack severity (25.0%) and 
duration (43.2%) (Table 3).  Significant change was seen in MIDAS (-47.66), HIT-6 (-7.62), 
HAD-A (-2.03), HAD-D (-2.81) and BDI-II (-6.43).  However, no significant improvements 
were observed in any quality of life measures (Table 4). 
Multiple phenotypes including CCH 
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In the 19 patients with multiple headache phenotypes, the mean follow-up time was 33.42 
months (range 13-76).  The 50% response rate at final follow-up was 52.6% (n=10) which 
was not significantly different to that of CCH alone (p=0.973).  Change in daily attack 
frequency over follow-up is shown in figure 1b.  No difference was seen in change in daily 
attack frequency between the groups at any time-point.  Significant improvements were also 
seen in attack intensity (28.8%) and duration (43.5%) (Table 3).   
In responders, 4/8 CM showed improvement (defined as a more than 30% improvement in 
moderate-to-severe headache days) and 3/4 SUNHA also showed improvement (defined as a 
50% or more reduction in daily attack frequency).  In non-responders, 5/8 CM improved with 
ONS. 
Those with multiple phenotypes showed significant improvements in HIT-6 (-6.10) and EQ-
VAS (10.38) scales but in no other disability, affect or quality of life measurement (Table 4). 
Triptan use 
With regards to triptans, 9 patients stopped and 13 were able to decrease their use by more 
than 50%.  Monthly triptan use was 36.82 ±32.7 (range 0-112) prior to and 19.51 ±33.07 
(range 0-120) post ONS (p<0.001).  The average cost in the UK for injectable Sumatriptan is 
currently £20.50 a dose translating to a saving of £407.19 ±514.98 (range 0-£1722) per-
patient per-month.  Responders averaged a monthly reduction of 29.37 ±25.76 doses 
(p<0.001) resulting in a saving of £604.37 ±519.52 per-patient per-month (Supplementary 
Table 3c).   
Preventative medication use 
Twenty-seven patients were taking preventative medications at baseline.  Four patients were 
able to stop all preventative medications and in total 17 patients made reductions to their 
drugs. 
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Time to effect and recurrence of attacks 
Time to first reported 50% improvement in cluster headache attacks was recorded in 37 
patients with a mean of 6.86 months ±7.33 (range 1-42).  Time to reach maximum reported 
improvement was 21.69 months ±15.06 (range 2-54).  Eighteen patients had their ONS 
switched off at some point (13 due to battery depletion, five due to lack of efficacy and one 
due to explantation).  The mean time of ONS switch-off in these subjects was 7.29 months 
(range 2-18).  In 12 of these patients (66.7%), CCH worsened within a mean of 6.57 weeks of 
switch off (range 1-12).        
 
Stimulation settings 
A range of settings was employed in order to achieve the widest area of occipital 
paranesthesia possible.  The range of amplitudes for Medtronic devices was 0.3-5.0V (mean 
2.4V, median 1.5V), pulse width 309-594µsec (mean 418µsec) and frequency 58-137Hz 
(mean 69.5Hz).  For St Jude devices; amplitude range was 0.5-2.7mA (mean 2.5mA, median 
1.7mA), frequency 70-177Hz (mean 96Hz) and pulse width 309-450 µsec (mean 415 µsec). 
 
Adverse events 
A total of 81 events were recorded affecting a total of 35 patients (Table 5).  The most 
common event was the need for battery replacement in 19 patients (37.3%), however, only 6 
of these were deemed unexpected battery failure of under a year.  Thirty-eight events 
required surgical intervention, although accounting for “expected” battery depletion this fell 
to 19.  One patient (2.0%) suffered lead migration and two (3.9%) from erosion of electrodes 
through the skin.  One infection was reported (2.0%) requiring medical intervention only. 
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DISCUSSION AND CONCLUSIONS 
This is the largest series with prolonged follow-up period for ONS in CCH.  In line with 
previous series (Table 5) we report that ONS appears to have a positive and sustained effect 
on otherwise refractory patients [1; 2; 4; 5; 12; 14; 17].  The most recent publications of long 
term follow up from Magis et al. and Leone et al. have both been on long-term follow up of 
ONS CCH patients [10; 13].  Magis et al.  had a mean of 5.7 years follow up in 10 patients 
and reported a 70% reduction in attack frequency but no change in preventative drug use.  
Leone et al. described a responder rate of 66.7% in 30 patients with a median follow-up of 
6.1 years with 10% of patients reducing preventative medications.  In our group of 51 highly 
complex patients after mean follow-up of 39.17 months there was a significant improvement 
in mean attack frequency with 24 patients remaining pain free for prolonged periods of time 
over follow-up.  Overall 52.9% of all patients exhibited response to ONS at final follow-up.  
There are a number of reasons why our response rate appears lower than previous series.  
Firstly, our series had a complex cohort of patients.  From available data our patients had a 
longer duration of chronic disease, had failed more medications and over 1/3 had co-existing 
headache disorders whereas previous series had CCH alone.  Our data suggests that there is 
no difference in outcomes of those with or without multiple headache types, a finding that is 
in opposition to general clinical belief.  However, this needs to be clarified in larger cohorts 
of complex patients.  Other factors include possible reporting bias in small series, for 
example the exclusion of patients whose devices were explanted, and the use of a trial 
stimulation period that we did not employ.  Although no evidence exists for trial stimulation 
reliably selecting responders, removing those who do not respond may subject remaining 
patients to positive selection bias. 
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Headache disability scales, affect and quality of life scales did show improvement with ONS 
but those in the quality of life measures were not significant in the whole cohort.  However, 
subgroup analysis of responder vs. non-responders showed a lack of improvement in any 
field in the non-responder cohort (Supplementary Table 2).  The failure to observe significant 
change across all quality of life measures despite improvements in attack frequency does not 
indicate lack of efficacy.  Similar observations have been made previously in ONS for 
chronic migraine [3] and is thought to reflect a “burden of normality” wherein patients have 
difficulty adjusting to the change in their new improved health status.  Previous authors have 
also suggested that a lack of prolonged functional outcome is seen in the long-term following 
ONS for CM, speculation this is due to the loss of an initial “honeymoon period” in 
patients[3].  Issues regarding the suitability of the scales in measuring headache populations 
have also been raised [25].  Specific to our cohort, given that 37.3% had multiple phenotypes 
that did not all necessarily respond to ONS a significant proportion of patients would still 
exhibit a burden from these headaches, even if CCH had significantly improved.  This is 
supported by a difference in disability scores in those with multiple phenotypes vs. CCH 
alone (Table 4). 
As in previous series [2; 5; 14; 15], subjects reported a delay of several months before 
achieving a response (6.86 months) and suffered relapses within weeks of stopping 
stimulation.  These observations suggest that there is a slow but reversible neuroplastic 
response to successful ONS.  
The cost and adverse event profile of ONS for headache treatment have been a cause for 
controversy in the past.  A recent paper estimated the mean treatment costs of ONS to be 
around £20,500 per case in a two year period [17].  Although the treatment cost is high, the 
direct cost from patients on society is significant.  In our series, cost per patient in the UK 
from triptans alone was over £9000 per year (based on mean triptan use per patient of 37 
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doses a month at cost of £20.50 per dose).  Following ONS, we estimate that patients reduced 
this expense by £4886 per annum with responders saving an average of £7252 per year.  Non-
responders showed a smaller saving (£2224 per annum).  This non-significant reduction 
reflects patients in this group having derived some benefit from the procedure even if they 
did not reach the dictated 50% improvement in attack frequency.  Shorter or less painful 
attacks mean patients avoided using triptans or oxygen.  This saving combined with a third of 
patients reducing preventative drugs and the significant improvements in quality of life 
measures all provide a positive balance to the initial cost of treatment.  Using above figures 
for cost of implant and changes in triptan doses, we estimate that the time to cost-
effectiveness from reduction in triptan use alone is 3 years in responders (4 years in the 
whole group and 9 years in non-responders)  
Adverse events in our series were much lower than those described in previous cohorts.  In 
small series lead migration rates vary from 7- 50% [2; 5; 14; 22], lead fracture rates from 10-
15% [2; 14; 19] and infection 10-20% [2; 14; 19].  Corresponding rates in our series were 
2%, 0% and 2% respectively.  The primary need for repeated surgery post-implant was to 
replace the battery (37.3%), however, the use of rechargeable batteries in recent years should 
lead to a decrease in surgical interventions and this is something we intend to explore in 
future publications.  Our implants were all conducted by a single highly skilled surgical team.  
A small number of experienced surgeons conducting larger numbers of procedures have been 
related to lower adverse event rates [23] and our data supports this.   
Weaknesses of the study include the lack of a placebo.  This has been a major problem in 
ONS research, as it is believed paresthesia is a requirement of response.  However, it is most 
unlikely that our observations are explained by placebo alone.  The previous intractability, 
stable time to response across cohorts, sustained response after prolonged follow-up and 
relapse with ONS failure all argue against a pure placebo response.  The placebo controlled 
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trials of ONS in migraine suggest a low placebo rate  (6% [21], 17.3% [24] and 20% [11]) 
and there is no reason to expect different rates in cluster headache [18].   
Strengths of the study include the large sample, prolonged follow-up, the prospective data 
collection and the “real life” nature of the data.  All subjects were patients in a single 
specialist center implanted due to clinical need in a healthcare system where ONS was only 
available as a last-line treatment.  The group is different from some previous cohorts in its 
complex nature and highly intractable nature.  A reduction in attack frequency of nearly 50% 
in such a highly intractable group, having suffered chronic cluster headache for a mean of 
7.88 years and having failed an average of 12.57 prior treatments, is a remarkable 
achievement.  
Our group has recently published the outcomes of a similar complex patient group of 21 
patients with CCH undergoing ventral tegmental area deep brain stimulation, 29% of which 
had failed ONS.  A reduction in daily attack frequency of 60% was recorded with a 50% or 
more reduction in attack frequency achieved in 52%.  Given the similar response rate and the 
more invasive nature of deep brain stimulation, it is clear that ONS should be considered first 
in CCH. 
In conclusion, ONS can provide a marked and sustained benefit in highly intractable chronic 
cluster headache control even after a mean follow up of 3 years.  Adverse event rates are low 
when implants are conducted in highly specialist centers.  The initial cost of implantation 
may be offset by the reduced need for acute medications and improved quality of life.       
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 N=51 
ONS Manufacturer 
Medtronic 
St Jude Medical 
 
48 (94.1%) 
3 (5.9%) 
IPG  
Standard 
Rechargeable 
Standard changed to rechargeable 
 
8 (15.7%) 
27 (52.9%) 
16 (31.4%) 
Electrodes 
Octad 
 
51 (100%) 
IPG, implantable pulse generator; ONS, occipital nerve stimulator 
Table 1: Information on the occipital nerve stimulator systems implanted 
 
 
 
 
 
 
 
 
 
 
Pg. 20 
 
 
Age 47.78 years (±9.73) 
Range 31-70 
Sex 
Male 
Female 
 
35 (68.6%) 
16 (31.4%) 
Attack Side 
Right 
Left 
Both 
 
32 (62.7%) 
15 (29.4%) 
4 (7.8%) 
Laterality 
Strictly unilateral 
Unilateral but side variable 
Bilateral 
 
41 (80.4%) 
7 (13.7%) 
3 (5.9%) 
Pattern 
Episodic transformed to chronic 
Chronic from onset 
 
30 (58%) 
21 (42%) 
Duration from onset of Cluster Headache  14.63 years (±11.0) 
Range 2-48 
Duration from onset of Chronic 
phase  
7.88 years (±6.44) 
Range 2-43 
Co-existent headache phenotypes 19 (37.3%) 
Number of headache phenotypes 
1 
2 
3 
 
32 (62.7%) 
16 (31.4%) 
3 (5.9%) 
Co-existent phenotypes 
CCH +CM 
CCH+SUNCT/SUNA 
CCH+CM+SUNCT/SUNA 
 
13 (25.5%) 
3 (5.9%) 
3 (5.9%) 
Mean number preventatives prior to 
ONS 
12.57 (±2.91) 
Range 7-21 
Response to GON block prior to ONS 21(41.2%) 
Follow up since implant 39.17 months (±19.04) 
Range 2-81 
CCH, chronic cluster headache; CM, chronic migraine; GON, Greater Occipital Nerve; ONS, Occipital nerve 
Stimulation; SUNA, short lasting unilateral neuralgiform headache attacks with autonomic features; SUNCT, 
short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing 
 
Table 2: Demographic data  
 
Pg. 21 
 
 
CCH, chronic cluster headache; CI, Confidence interval; ONS, Occipital nerve Stimulation; SD, Standard 
deviation; VRS, verbal rating scale  
Table 3: Summary of attack outcome measures 
 
Outcome Measure Prior 
ONS 
(n=51) 
Post 
ONS 
(n=51) 
Percentage 
Change 
Mean Difference 
(95%CI) 
 
P Value 
Whole Cohort 
Mean daily attacks 
(SD) 
Range 
3.73 
(±1.83) 
1-8 
2.12 
(±2.28) 
0-8 
46.1% 
(±43.69) 
0-100 
1.61 (0.88, 2.34) 
 
<0.001* 
Mean attack 
intensity (SD) 
Range (VRS) 
8.43 
(±1.61) 
5-10 
6.17 
(±3.54) 
0-10 
26.4% 
(±37.47) 
0-100 
2.27 (1.18, 3.35) 
 
<0.001* 
Mean attack 
duration (SD) 
Range (hours) 
1.66 
(±1.62) 
0.3-10.5 
0.85 
(±0.98) 
0.0-5.5 
43.3% 
(±39.27) 
0-100 
0.801 (0.46, 1.15) 
 
<0.001* 
CCH Alone (n=32) 
Mean daily attacks 
(SD) 
Range 
3.88 
(±1.69) 
1-8 
1.91 
(±2.10) 
0-7 
49.5% 
(±43.84) 
0-100 
1.96 (1.03, 2.90) <0.001* 
Mean attack 
intensity (SD) 
Range (VRS) 
8.22 
(±1.73) 
5-10 
6.64 
(±3.20) 
0-10 
25.0% 
(±36.56) 
0-100 
1.57 (0.34, 2.81) 0.014* 
Mean attack 
duration (SD) 
Range (hours) 
1.54 
(±1.05) 
0.3-4.0 
0.86 
(±0.78) 
0.0-2.8 
43.2% 
(±38.46) 
0-100 
0.68 (±0.30, 1.06) <0.001* 
Multiple Phenotypes (n=19) 
Mean daily attacks 
(SD) 
Range 
3.47 
(±2.06) 
1-8 
2.47 
(±2.59) 
0-8 
40.3% 
(±43.97) 
0-100 
1.00 (0.24, 2.24) 0.036* 
Mean attack 
intensity (SD) 
Range (VRS) 
8.79 
(±1.34) 
6-10 
5.37 
(±4.00) 
0-10 
28.8% 
(±39.83) 
0-100 
3.42 (1.32, 5.51) 0.003* 
Mean attack 
duration (SD) 
Range (hours) 
1.84 
(±2.32) 
0.3-10.5 
0.848 
(±1.27) 
0.0-5.5 
43.5% 
(±41.70) 
0-100 
0.99 (0.28, 1.71) 0.009* 
Pg. 22 
 
 Pre-ONS Post-ONS Change in score P value 
Whole Cohort (n=51) 
MIDAS (n=51) 
Mean (±SD) 
Range 
 
149.84 (±89.10) 
0-270 
 
114.92 (±106.66) 
0-270 
 
34.92 (±100.19) 
 
0.016* 
HIT-6 (=51) 
Mean (±SD) 
Range 
 
67.73 (±6.08) 
53-80 
 
60.68 (±13.07) 
10-78 
 
7.05 (±11.08) 
 
<0.001* 
HAD-A (n=51) 
Mean (±SD) 
Range 
 
12.16 (±5.005) 
1-21 
 
10.12 (±5.41) 
0-21 
 
2.04 (±5.63) 
 
0.013* 
HAD-D (n=51) 
Mean (±SD) 
Range 
 
12.04 (±4.68) 
1-21 
 
9.22 (±6.10) 
01-21 
 
2.82 (±5.56) 
 
0.001* 
BDI-II (n=49) 
Mean (±SD) 
Range 
 
27.59 (±14.45) 
0-55 
 
22.82 (±15.98) 
0-56 
 
4.77 (±13.66) 
 
0.018* 
EQ5D (n=49) 
Mean (±SD) 
Range 
 
0.69 (±0.11) 
0.55-1.00 
 
0.69 (±0.15) 
0.18-1.00 
 
0 (±0.11) 
 
1.00 
EQ-VAS (n=49) 
Mean (±SD) 
Range 
 
49.75 (±23.24) 
0-95 
 
52.42 (±27.62) 
5-95 
 
-2.67 (±17.08) 
 
0.285 
SF-36 P (n=51) 
Mean (±SD) 
Range 
 
32.12 (±9.97) 
13.70-52.30 
 
33.82 (±11.80) 
11.80-55.70 
 
-1.70 (±9.14) 
 
0.191 
SF-36 M (n=51) 
Mean (±SD) 
Range 
 
34.14 (±12.97) 
15.3-58.5 
 
38.34 (±14.79) 
14.70-62.70 
 
-4.20 (±13.95) 
 
0.036* 
Pg. 23 
 
CCH alone (n=32) 
MIDAS (n=32) 
Mean (±SD) 
Range 
 
156.25 (±91.19) 
0-270 
 
108.59 (±111.35) 
0-270 
 
47.66 (±108.65) 
 
 
0.019* 
 
HIT-6 (=32) 
Mean (±SD) 
Range 
 
67.91 (±6.31) 
53-80 
 
60.28 (±14.04) 
10-78 
 
7.62 (±11.94) 
 
0.001* 
HAD-A (n=32) 
Mean (±SD) 
Range 
 
12.81 (±4.30) 
3-21 
 
10.78 (+4.67) 
0-19 
 
2.03 (±5.43) 
 
0.043* 
HAD-D (n=32) 
Mean (±SD) 
Range 
 
12.28 (±4.48) 
1-20 
 
9.47 (±6.02) 
0-20 
 
2.81 (±5.39) 
 
0.006* 
BDI-II (n=32) 
Mean (±SD) 
Range 
 
28.34 (±14.23) 
0-52 
 
22.30 (±15.75) 
0-53 
 
6.43 (±11.67) 
0.005* 
EQ5D (n=30) 
Mean (±SD) 
Range 
 
0.70 (±0.11) 
0.55-1.00 
 
0.70 (±0.13) 
0.55-1.00 
 
0.00 (±0.09) 
 
0.908 
EQ-VAS (n=30) 
Mean (±SD) 
Range 
 
56.13 (±19.89) 
20-90 
 
55.00 (±24.25) 
10-95 
 
1.96 (±12.74) 
 
0.405 
SF-36 P (n=32) 
Mean (±SD) 
Range 
 
33.52 (±9.40) 
18.8-52.3 
 
35.06 (±10.82) 
11.80-53.20 
 
-1.54 (±8.93) 
 
0.337 
SF-36 M (n=32) 
Mean (±SD) 
Range 
 
33.99 (±13.38) 
16.60-58.20 
 
38.02 (±14.46) 
14.70-62.70 
 
-4.02 (±12.89) 
 
0.087 
Multiple phenotypes (n=19) 
Pg. 24 
 
MIDAS (n=19) 
Mean (±SD) 
Range 
 
139.05 (±86.80) 
8-270 
 
125.58 (±100.28) 
0-270 
 
13.47 (±82.34) 
 
0.485 
HIT-6 (=19) 
Mean (±SD) 
Range 
 
67.42 (±5.83) 
58-78 
 
61.32 (±11.58) 
42-78 
 
6.10 (±9.70) 
 
0.013* 
HAD-A (n=19) 
Mean (±SD) 
Range 
 
11.05 (±5.96) 
1-20 
 
9.00 (±6.44) 
0-21 
 
2.05 (±9.70) 
 
0.160 
HAD-D (n=19) 
Mean (±SD) 
Range 
 
11.63 (±5.39) 
1-21 
 
8.79 (6.38) 
0-21 
 
2.84 (±5.99) 
 
0.053 
BDI-II (n=19) 
Mean (±SD) 
Range 
 
25.79 (±14.37) 
5-55 
 
23.63 (±16.74) 
1-56 
 
2.158 (±16.33) 
 
0.572 
EQ5D (n=19) 
Mean (±SD) 
Range 
 
0.68 (±0.10) 
0.55-0.84 
 
0.68 (±0.17) 
0.18-1.00 
 
0.00 (±0.14) 
 
0.925 
EQ-VAS (n=19) 
Mean (±SD) 
Range 
 
39.11 (±25.02) 
0-95 
 
49.50 (±33.09) 
5-95 
 
-10.38 (±20.71) 
 
0.048* 
SF-36 P (n=19) 
Mean (±SD) 
Range 
 
29.77 (±10.70) 
13.70-49.00 
 
31.73 (±13.33) 
13.70-55.70 
 
-1.96 (±9.71) 
 
0.390 
SF-36 M (n=19) 
Mean (±SD) 
Range 
 
34.38 (±12.61) 
15.30-58.50 
 
38.90 (±15.69) 
14.80-59.50 
 
-4.51 (±15.94) 
 
0.233 
BDI-II, Beck Depression Inventory II; CCH, Chronic cluster headache; EQ5D, Euro-QoL 5D Index; Euro-VAS, Euro-QoL visual analogue score; HAD-A, Hospital Anxiety 
and Hospital Depression Scores – Anxiety component; HAD-D, Hospital Anxiety and Hospital Depression Scores – Depression component; HIT-6, Headache Impact Test 6 
Score; MIDAS, Migraine Disability Assessment Score; ONS, Occipital Nerve Stimulation; SD, Standard Deviation 
Pg. 25 
 
Table 4: Summary of headache-related disability and mental state scores 
 
 
 
 
 
 
 
 
 
 
 
 
Pg. 26 
 
 Adverse Event Total Events 
 
 
 
 
Hardware Related 
 
Lead migration 1 (2%) 
Electrode erosion 2 (4%) 
ONS system revision 
Rechargeable system 
Lead revisions (lead tethering) 
IPG revision secondary to pain 
6 (12%) 
2 (4%) 
2 (4%) 
2 (4%) 
Explantation 
Efficacy 
Lead tethering causing neck pain 
4 (8%) 
3 (6%) 
1 (2%) 
Battery depletion (Failure in under one year) 6 (12%) 
Battery replacement at any time 19 (37.3%) 
Total Hardware Related Events 38 
 
 
 
Biological 
Infection (superficial wound infection) 
(surgical action n=0) 
1 (2%) 
 
Pain over IPG/lead/wound sites 
(surgical action n=2) 
12 (24%) 
Neck stiffness 
(surgical action n=0) 
8 (16%) 
Allergy to surgical material 2 (8%) 
Wound site complication 
Keloid scar 
Idiopathic Urticaria 
(surgical action n=0) 
3 (6%) 
2 (4%) 
1 (2%) 
Total Biological Related Events 26 
Stimulator Associated Undesirable changes in stimulation 
(surgical action n=0) 
17 (33%) 
Total Stimulator Associated Events 17 
TOTAL   81 events 
IPG, implantable pulse generator; ONS, Occipital nerve stimulator 
 
Table 5: Adverse events 
Pg. 27 
 
Study Num
ber 
of 
Patie
nts 
Mea
n 
age 
(yea
rs) 
Chro
nic  
Durat
ion 
(years
) 
Mean 
Number 
Preventa
tives 
Failed 
Mean 
Follo
w-up 
[rang
e] 
(mont
hs) 
Patien
ts 
impro
ved 
>50% 
Chang
e 
attack  
Freque
ncy 
 
Chan
ge 
attac
k 
Seve
rity 
Chan
ge 
attac
k 
Durat
ion 
Prevent
ative 
Treatm
ent 
Reducti
on 
Magis 
200715,2
01112 
14 47.6 7.07 >4* 36.62 
[11-
64] 
12/14 
(86%) 
-94.6% +2.3
% 
N/A  4/14 
Burns 
200716,2
00910 
14 44 6 >4** 
 
17.5 
[4-35] 
10/14 
(71%) 
-33% +8% -23% 6/14 
(triptans
) 
De 
Quinta
na 
201017 
4 42 - - 6+ 4/4 
(100%
) 
-56% -48% -
63.8% 
3/14 
Fontain
e 
201111 
13 44.6 9.8 >4* 14.6 
[3-34] 
10/13 
(76%) 
-68% -49% N/A 8/13 
Muelle
r 
201320 
24 30 - >3 21.5 
[4-47] 
21/24 
(88%) 
-40% -38% N/A - 
(40% 
reductio
n daily 
triptan 
dose) 
Magis 
201613 
 
10 
47.6 7 >4* 71 
[54-
103] 
9/10 
(90%) 
-70.8% N/A N/A 4/10 
Leone 
201610 
30 42 6.7 N/A 73.2 
[2-11] 
20/30 
(66.7
%) 
N/A N/A N/A 0 
Our 
Study 
51 47.7
8 
7.88 12.57 
 
39.17 
[2-81] 
27/51 
(52.9
%) 
-
46.14
% 
-
26.47
% 
-
43.35
% 
21/27† 
(26/ 
51tripta
ns) 
*As per ICHD definition of “intractable chronic cluster headache”; **Patients failed mean 9 
preventatives in 2007 study; +No range given; †31 patients on preventative medication at implant 
 
Table 6: Comparison of outcomes for occipital nerve stimulation in chronic cluster 
headache 
 
Pg. 28 
 
 
 
 
 
 
 
Figure 1a: Improvement of daily cluster attack frequency of entire cohort over follow-up
Pg. 29 
 
 
 
Follow-up 
(months) 
Baseline 3  6 9 12 18 24 36 48  Final follow-
up 
CCH alone 32 32 31 31 31 28 24 21 16 32 
Multiple 
Phenotypes 
19 19 19 19 19 16 14 8 3 19 
p-value N/A 0.784 0.975 0.482 0.332 0.965 0.701 0.112 0.806 0.469 
 
CCH, chronic cluster headache; N/A, not applicable 
 
 
Figure 1b: Improvement in daily cluster attack frequency of those with chronic cluster 
headache alone compared to those with multiple phenotypes over follow-up.  Table provides 
number of subjects included at each time point and p-value for difference in improvement 
between the groups. 
 
Figure 1: Changes in improvement in daily cluster headache attack frequency following 
occipital nerve stimulation 
 
 
 
Pg. 30 
 
 Number of patient 
who have tried drug 
(%) 
Daily dose range (mg) Mean maximum daily 
dose (mg) 
Verapamil 51 (100) 240-1200 762 
Lithium 49 (96.8) 200-2800 1014 
Topiramate 39 (76.2) 25-800 232 
Melatonin 39 (76.2) 4-15 13 
Gabapentin 47 (92.1) 300-3600 2155 
Pregabalin 34 (66.7) 150-1000 491 
Valproate 35 (68.3) 50-3000 1110 
Methysergide 46 (92.1) 2-27 9 
Baclofen 9 (17.5) 10-90 57 
Corticosteroid 36 (69.8) - - 
IV DHE 44 (85.7) - - 
GONB 48 (93.7) - - 
 
GONB, greater occipital nerve block; IV DHE, intravenous dihydroergotamine;  
 
Supplementary Table 1. Medications taken for cluster headache prior to occipital nerve 
stimulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pg. 31 
 
 Responders (n=27) Non-Responders (n=24) 
 Pre-ONS Post-ONS P value Pre-ONS Post-ONS P value 
Headache Disability Scores 
MIDAS N=27 153.11(±96.26) N=27 79.04 (±101.36) 0.001* N=24 146.17 (±82.21) N=24 155.29 (±99.52) 0.581 
HIT-6 N=27 67.04 (±5.68) N=27 55.15 (±13.69) <0.001* N=24 68.50 (±6.54) N=24 66.88 (±9.13) 0.343 
Affect Scores 
HAD-A N=27 12.19 (±4.89) N=27 8.04 (±4.75) <0.001* N=24 12.13 (±5.23) N=24 12.46 (±5) 0.786 
HAD-D N=27 11.11 (±4.93) N=27 6.33 (±5.53) <0.001* N=24 13.08 (±4.52) N=24 12.46 (±5).06 0.452 
BDI-II N=27 23.65 (±12.76) N=27 14.92 (±10.84) <0.001* N=24 32.04 (±15.21) N=24 31.74 (±16.33) 0.921 
Quality of Life Scores 
Euro-QoL 
Euro-QoL N=26 0.75 (±0.09) N=26 0.75 (±0.13) 0.693 N=22 0.63 (±0.10) N=22 0.62 (±0.13) 0.719 
Euro-Scale N=26 61.42 (±18.17) N=26 68.12 (±19.17) 0.106 N=22 35.95 (±21.54) N=22 38.86 (±24.58) 0.373 
SF-36 
SFP N=27 34.40 (±9.48) N=27 37.72 (±11.66) 0.106 N=24 29.56(±10.07) N=24 29.43(±10.55) 0.932 
SFM N=27 36.25 (±13.76) N=27 44.69 (±13.31) 0.008* N=24 31.64 (±13.49) N=24 30.95 (±13.14) 0.933 
BDI-II, Beck Depression Inventory II; HAD-A, Hospital Anxiety and Hospital Depression Scores – Anxiety component; HAD-D, Hospital 
Anxiety and Hospital Depression Scores – Depression component; HIT-6, Headache Impact Test 6 Score; MIDAS, Migraine Disability 
Assessment Score; ONS, Occipital Nerve Stimulation; SF-36, short form 36-item health survey. SF-36 subscales: PF, physical function; RP, role 
Pg. 32 
 
physical; BP, bodily pain; GH, general health; VT, vitality; SF, social function; RE, role emotional; MH, mental health. SF-36 composite 
domains: SFP, physical component; SFM, mental component 
Supplementary Table 2: Headache disability and quality of life scales by treatment response 
 
 
 
 
 
 
 
 
 
 
 
Pg. 33 
 
 
 Responders (n=36) Non-responders (n=27) 
Pre-ONS Post-ONS P-value Pre-ONS Post-ONS P-value 
Mean daily attacks (SD) 3.89 (±1.98) 0.48 (±0.70) <0.001* 3.54 (±1.67) 3.96 (±2.03) 0.253 
Mean attack intensity 
(SD) [VRS] 
8.94 (±1.31) 4.63 (±4.01) <0.001* 7.85 (±1.74) 7.90 (±1.78) 0.858 
Mean attack duration 
(SD) [hours] 
1.59 (±1.06) 0.45 (±0.58) <0.001* 1.74 (±2.11) 1.31 (±1.14) 0.111 
 
B. 
 Responder Non Responder P Value 
Mean final patient estimate 
% 
78.87 (±26.63) 25.63 (±29.57) <0.001* 
Maximum patient estimate 
% 
88.37 (±19.61) 40.42 (±32.53) <0.001* 
 
C: 
 Responders (n=36) Non-responders (n=27) 
Pre-ONS Post-ONS P-value Pre-ONS Post-ONS P-value 
Mean monthly triptan 
dose (SD) 
Range  
33.78 (±28.11) 4.41 (±7.69) <0.001* 40.25 (±36.72) 36.50 (±41.73) 0.467 
Pg. 34 
 
Mean monthly triptan 
cost per-patient(SD)  
Range (£) 
£692.44 
(±576.20) 
£90.35 (±157.69) <0.001* £825.13 
(±752.74) 
£748.25 
(±855.64) 
0.467 
 
ONS, Occipital nerve Stimulation; SD, Standard deviation; VRS, verbal rating scale  
Supplementary Table 3: Headache outcome measures (A), patient estimate of improvement (B) and triptan use(C) by response to 
occipital nerve stimulation 
 
